Lentiviral Vectors and Gene Therapy

Gene therapy was conceived during the early and mid part of the 20th century. At first, it was considered a revolutionary biomedical procedure, which could potentially cure any disease for which the molecular bases were understood. Since then, gene therapy has gone through many stages and has evolved from a nearly unrealistic perspective to a real life application. Clinical efficacy in humans was demonstrated at the beginning of this century after its successful application in small-scale clinical trials to cure severe immunodeficiency in children. However, their successes were overshadowed some time later by the occurrence of vector-related leukaemia in a number of treated children. It is in this context that lentiviral vectors have appeared, with improved efficiency and, possibly, increased biosafety. Very recently, the first clinical trials with lentivectors have been carried out with some success.

This Brief firstly defines gene therapy, and places lentivectors within this fascinating therapeutic strategy. Then follows a comprehensive description of the development of retroviral and lentiviral vectors and how to specifically target distinct cell types and tissues. The authors also discuss the application of lentivector gene therapy for the treatment of cancer and autoimmune diseases, ending with the application of lentivectors in human gene therapy clinical trials.

• cancer
• clinical trial
• gene therapy
• lentivector
• promoter
• viral immunology
• genetic engineering

• Rayne Institute, Division of Infection and Immunity, University College, London, United Kingdom

  David Escors

• Medical School, Department of Physiology-Immunology, Free University of Brussels, Jette, Belgium

  Karine Breckpot

• University College London, London, United Kingdom

  Frederick Arce, Holly Stephenson

• , Nuffield Orthopaedic Centre, University of Oxford, Oxford, United Kingdom

  Grazyna Kochan

Policies and ethics